NASDAQ:CERS Cerus (CERS) Stock Price, News & Analysis → The new masters of energy (From Porter & Company) (Ad) Free CERS Stock Alerts $1.78 -0.11 (-5.82%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.77▼$1.9150-Day Range$1.62▼$2.0452-Week Range$1.21▼$3.08Volume551,799 shsAverage Volume1.36 million shsMarket Capitalization$329.10 millionP/E RatioN/ADividend YieldN/APrice Target$3.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cerus alerts: Email Address Cerus MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside115.4% Upside$3.83 Price TargetShort InterestHealthy3.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.46Based on 2 Articles This WeekInsider TradingSelling Shares$372,912 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.09) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.53 out of 5 starsMedical Sector438th out of 905 stocksSurgical & Medical Instruments Industry55th out of 97 stocks 3.3 Analyst's Opinion Consensus RatingCerus has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCerus has only been the subject of 2 research reports in the past 90 days.Read more about Cerus' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.25% of the outstanding shares of Cerus have been sold short.Short Interest Ratio / Days to CoverCerus has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cerus has recently increased by 5.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCerus does not currently pay a dividend.Dividend GrowthCerus does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CERS. Previous Next 2.5 News and Social Media Coverage News SentimentCerus has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cerus this week, compared to 2 articles on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cerus insiders have sold 3,754.39% more of their company's stock than they have bought. Specifically, they have bought $9,675.00 in company stock and sold $372,912.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cerus is held by insiders.Percentage Held by Institutions78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cerus' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cerus are expected to grow in the coming year, from ($0.09) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cerus is -10.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cerus is -10.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCerus has a P/B Ratio of 6.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cerus' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t have access to electricity right now.” And early investors could make a fortune.Click here to get all the details. About Cerus Stock (NASDAQ:CERS)Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.Read More CERS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CERS Stock News HeadlinesJune 4, 2024 | americanbankingnews.comShort Interest in Cerus Co. (NASDAQ:CERS) Increases By 5.1%May 22, 2024 | businesswire.comCerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor ConferenceMay 5, 2024 | markets.businessinsider.comCerus’s Strong Q1 Growth and Promising INTERCEPT Technology Drive Buy RatingMay 4, 2024 | finance.yahoo.comCerus First Quarter 2024 Earnings: EPS Misses ExpectationsMay 3, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Joint (JYNT) and Cerus (CERS)May 3, 2024 | finance.yahoo.comCerus Corp (CERS) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...May 3, 2024 | finance.yahoo.comQ1 2024 Cerus Corp Earnings CallMay 3, 2024 | finance.yahoo.comCerus Corporation (NASDAQ:CERS) Q1 2024 Earnings Call TranscriptMay 2, 2024 | investorplace.comCERS Stock Earnings: Cerus Meets EPS, Misses Revenue for Q1 2024May 2, 2024 | sfgate.comCerus: Q1 Earnings SnapshotMay 2, 2024 | finance.yahoo.comCerus Corp (CERS) Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss NarrowsMay 2, 2024 | businesswire.comCerus Corporation Announces First Quarter 2024 Financial ResultsApril 26, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Cerus (CERS), MiMedx Group (MDXG)April 18, 2024 | finance.yahoo.comCerus Corporation (NASDAQ:CERS) is a favorite amongst institutional investors who own 64%April 18, 2024 | businesswire.comCerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024April 12, 2024 | markets.businessinsider.comCerus Corporation: Strong Buy Rating Amidst Growth and Path to ProfitabilityApril 12, 2024 | msn.comCerus gains as Craig Hallum launches at Buy on return to growthMarch 28, 2024 | stockhouse.comCerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf LifeMarch 26, 2024 | markets.businessinsider.comCerus: FDA Approves 12-month Shelf Life For INTERCEPT Platelet Processing SetsMarch 26, 2024 | finance.yahoo.comCerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf LifeMarch 19, 2024 | msn.comWhy Blood Components-Focused Cerus Stock Is Rising TuesdayMarch 19, 2024 | markets.businessinsider.comCerus’s Strong Q4 Performance and Positive 2024 Outlook Prompt ‘Buy’ RatingMarch 19, 2024 | markets.businessinsider.comCerus Announces Positive Results For Phase 3 Trial Of Intercept Blood SystemMarch 19, 2024 | msn.comCerus' soars on meeting main goal of late stage trial for INTERCEPT RBCs in heart surgery patientsMarch 19, 2024 | finance.yahoo.comCerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery PatientsSee More Headlines Receive CERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/08/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:CERS CUSIP15708510 CIK1020214 Webwww.cerus.com Phone(925) 288-6000Fax925-288-6001Employees625Year Founded1991Price Target and Rating Average Stock Price Target$3.83 High Stock Price Target$5.00 Low Stock Price Target$2.50 Potential Upside/Downside+115.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,490,000.00 Net Margins-19.27% Pretax Margin-19.16% Return on Equity-58.65% Return on Assets-15.14% Debt Debt-to-Equity Ratio1.29 Current Ratio2.41 Quick Ratio1.72 Sales & Book Value Annual Sales$156.37 million Price / Sales2.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book6.14Miscellaneous Outstanding Shares184,890,000Free Float178,604,000Market Cap$329.10 million OptionableOptionable Beta1.26 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. William M. Greenman (Age 57)President, CEO & Director Comp: $1.04MMr. Kevin D. Green (Age 52)VP of Finance & CFO Comp: $607.53kMr. Vivek K. Jayaraman (Age 49)Chief Operating Officer Comp: $696.68kMs. Chrystal Jensen (Age 53)Chief Legal Officer & General Counsel Comp: $571.49kDr. Richard J. Benjamin MBChB (Age 64)Ph.D., Chief Medical Officer Comp: $603.68kDr. Laurence M. Corash (Age 80)Co-Founder & Chief Scientific Officer Comp: $697.77kMs. Lori L. RollVP of Administration & Corporate SecretaryMr. Matthew M. NotarianniSenior Director of Investor RelationsLainie CortenVice President of Global MarketingMs. Alicia GoodmanChief Human Resources OfficerMore ExecutivesKey CompetitorsAtrionNASDAQ:ATRIAnika TherapeuticsNASDAQ:ANIKOraSure TechnologiesNASDAQ:OSURUtah Medical ProductsNASDAQ:UTMDCardiovascular SystemsNASDAQ:CSIIView All CompetitorsInsiders & InstitutionsSilvercrest Asset Management Group LLCBought 114,628 shares on 5/16/2024Ownership: 1.458%California State Teachers Retirement SystemSold 11,366 shares on 5/16/2024Ownership: 0.010%Hood River Capital Management LLCBought 299,694 shares on 5/15/2024Ownership: 0.162%Price T Rowe Associates Inc. MDBought 8,982 shares on 5/15/2024Ownership: 0.104%Public Employees Retirement Association of ColoradoSold 51,985 shares on 5/15/2024Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions CERS Stock Analysis - Frequently Asked Questions Should I buy or sell Cerus stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CERS shares. View CERS analyst ratings or view top-rated stocks. What is Cerus' stock price target for 2024? 3 equities research analysts have issued 12 month target prices for Cerus' stock. Their CERS share price targets range from $2.50 to $5.00. On average, they predict the company's stock price to reach $3.83 in the next year. This suggests a possible upside of 115.4% from the stock's current price. View analysts price targets for CERS or view top-rated stocks among Wall Street analysts. How have CERS shares performed in 2024? Cerus' stock was trading at $2.16 at the beginning of 2024. Since then, CERS stock has decreased by 17.6% and is now trading at $1.78. View the best growth stocks for 2024 here. Are investors shorting Cerus? Cerus saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 6,010,000 shares, an increase of 5.1% from the April 30th total of 5,720,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is presently 3.9 days. View Cerus' Short Interest. When is Cerus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our CERS earnings forecast. How were Cerus' earnings last quarter? Cerus Co. (NASDAQ:CERS) announced its earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The biotechnology company had revenue of $38.37 million for the quarter, compared to the consensus estimate of $36.40 million. Cerus had a negative trailing twelve-month return on equity of 58.65% and a negative net margin of 19.27%. What ETFs hold Cerus' stock? ETFs with the largest weight of Cerus (NASDAQ:CERS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG).ARK Innovation ETF (ARKK). What guidance has Cerus issued on next quarter's earnings? Cerus issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $172.0 million-$175.0 million, compared to the consensus revenue estimate of $190.9 million. What is William M. (Obi) Greenman's approval rating as Cerus' CEO? 15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Cerus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA). Who are Cerus' major shareholders? Cerus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.40%), Nikko Asset Management Americas Inc. (4.19%), Sumitomo Mitsui Trust Holdings Inc. (4.28%), Wasatch Advisors LP (3.47%), Silvercrest Asset Management Group LLC (1.46%) and Assenagon Asset Management S.A. (0.61%). Insiders that own company stock include Ann Lucena, Carol Moore, Chrystal Jensen, Chrystal Menard, Daniel N Swisher Jr, Eric Bjerkholt, Gail Schulze, Hua Shan, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Vivek K Jayaraman and William Mariner Greenman. View institutional ownership trends. How do I buy shares of Cerus? Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CERS) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerus Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.